Biotech Acquisition ^{Priced, Nasdaq: BIOT}

We are a recently organized blank check company. While we may pursue an acquisition opportunity in any business, industry, or sector, we intend to focus on industries that complement our sponsor and management team’s background as affiliates of SPRIM Global Investments, a leading life science investment firm in the healthcare industry (which we refer to herein as SPRIM). As such, our target sector is expected to be the healthcare industry, with a particular focus on life sciences/biotechnology, healthcare information technology, medical technology and technology-enabled healthcare service sectors. More specifically, in biotechnology, we expect to focus on platform biotech companies (i.e., companies with broad underlying technologies that have or could create multiple drug candidates), while in digital health, we expect to our focus will be on business-to-business (or B2B) enterprise software solutions. The management team leverages the SPRIM dual vantage point as a global contract research organization (or CRO) and an investor in biotech and digital health. SPRIM is at the center of an eco-system of emerging biopharma, CRO partners and health tech companies.